







A Critical Medicines Alliance for Europe

This Critical Medicines Alliance is a new consultative mechanism bringing together national authorities, industry, civil society, the Commission and EU agencies to identify the best measures to address and avoid shortages of critical medicines. It complements regulatory measures in the proposed EU pharmaceutical reform and is at the centre of the new strategic and coordinated industrial approach to enhance security of supply of the most critical medicines*.

24 April 2024

How will the Alliance achieve this?

It will help decision makers to develop a dedicated industrial policy toolbox to tackle shortages of critical medicines through actions such as:

-  **EU funding**, as well as possible coordination with national funding to enable investment in manufacturing projects
-  **partnerships** with third countries to secure supply chains
-  **market incentives**, such as capacity reservation contracts
-  **joint procurement** to enhance security of the supply of critical medicines throughout the EU

Next steps

- The Alliance will use the outcome of the pilot assessment of critical medicines as a point of reference
- As of May, members of the Alliance will collaborate in thematic Working Groups
- Over the course of Q4 2024, the Working Groups will make recommendations based on the identified vulnerabilities
- By the end of 2024, the Steering Board will come forward with a Strategic Plan, which the Alliance Forum will consider and endorse
- This plan will establish a multi-annual set of actions aimed at guiding the work of EU decision makers
- The initial mandate of the Alliance is of 5 years



Forum

- Open to all Member Organisations
- Convenes at least once a year to discuss high-level policy matters concerning the Alliance
- The Forum will be consulted before the Steering Board adopts the Strategic Plan

Steering Board

- In charge of the Strategic Plan and its implementation
- Member States
- Industry
- Patients and healthcare professionals
- Executive Steering Group on Shortages & Safety of Medicinal Products (MSSG)
- European Medicines Agency (EMA)
- All chairs of the Working Groups

Governance structure



Working Groups

- Focusing on specific topics, these groups are open for participation to Member Organisations with relevant activities and expertise related to the designated Working Group's area of work
- They provide input to the Steering Board to aid with the drafting of the Strategic Plan

*As defined by the Union list of critical medicines.